SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery ...

SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery ...

Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials

SpyGlass Pharma Raises $75M Series D Funding

SpyGlass Pharma, an Aliso Viejo, CA-based ophthalmic biotechnology company, raised $75M in Series D funding. The round was led by Sands Capital, joined by Gilde Healthcare and existing investors New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC. The company intends to use the funds for the advancement of its […] The post SpyGlass Pharma Raises $75M Series D Funding appeared first on FinSMEs.

SpyGlass Pharma raises $75M for drug delivery platform

SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform. Sands Capital led the financing round, with Gilde Healthcare also joining. Existing investors New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC participated. The company said funds support its drug delivery platform capable of providing multiple years of therapy. It add…